Entera Bio Ltd. cotiza a 2.65 USD y tiene una capitalización bursátil de $461M. En los últimos 12 meses ha facturado $0 con un margen de flujo de caja libre del -17802.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of s…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.14 | $-0.07 | $-0.06 |
| Estimado | $-0.07 | $-0.08 | $-0.08 | $-0.09 |
| Sorpresa | — | -75.0% | +12.5% | +33.3% |
| Métrica | ENTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 0.0% | 57.0% | -57.0% |
| Operating Margin | -27450.0% | -38.6% | -27411.4% |
| Net Margin | -27235.7% | -33.6% | -27202.1% |
| FCF Margin | -17802.4% | -13.9% | -17788.5% |
| ROE | -87.3% | -40.4% | -46.9% |
| ROA | -71.5% | -32.0% | -39.5% |
| Current Ratio | 6.94 | 2.84 | +4.10 |
| Debt / Equity | — | 0.28 | — |